Clinical Trial Update: Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating CYT107 (recombinant glycosylated human interleukin-7) for Kaposi sarcoma in people with HIV and immune non-response; recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kaposi Sarcoma

Drugs mentioned

• CYT107 (CYT107)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Kaposi Sarcoma | Phase 2 | Status: RECRUITING